Lazard Asset Management LLC Sells 86,458 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Lazard Asset Management LLC decreased its holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 13.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 555,850 shares of the company's stock after selling 86,458 shares during the period. Lazard Asset Management LLC owned 0.14% of Recursion Pharmaceuticals worth $3,757,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Ensign Peak Advisors Inc boosted its holdings in Recursion Pharmaceuticals by 0.3% in the 4th quarter. Ensign Peak Advisors Inc now owns 410,286 shares of the company's stock worth $2,774,000 after buying an additional 1,300 shares during the period. Farther Finance Advisors LLC boosted its holdings in shares of Recursion Pharmaceuticals by 21.1% in the fourth quarter. Farther Finance Advisors LLC now owns 7,757 shares of the company's stock worth $52,000 after acquiring an additional 1,353 shares during the period. Summit Investment Advisors Inc. boosted its holdings in shares of Recursion Pharmaceuticals by 7.8% in the fourth quarter. Summit Investment Advisors Inc. now owns 26,030 shares of the company's stock worth $176,000 after acquiring an additional 1,875 shares during the period. Wedmont Private Capital grew its position in shares of Recursion Pharmaceuticals by 10.6% in the fourth quarter. Wedmont Private Capital now owns 20,943 shares of the company's stock valued at $144,000 after purchasing an additional 2,000 shares in the last quarter. Finally, Daiwa Securities Group Inc. lifted its holdings in Recursion Pharmaceuticals by 28.3% during the 4th quarter. Daiwa Securities Group Inc. now owns 10,135 shares of the company's stock worth $69,000 after purchasing an additional 2,235 shares in the last quarter. Institutional investors own 89.06% of the company's stock.

Recursion Pharmaceuticals Price Performance

Shares of RXRX traded down $0.44 during trading hours on Wednesday, reaching $4.12. 19,958,645 shares of the company's stock traded hands, compared to its average volume of 13,253,762. Recursion Pharmaceuticals, Inc. has a 12 month low of $3.79 and a 12 month high of $12.36. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04. The stock has a market cap of $1.67 billion, a PE ratio of -2.70 and a beta of 0.99. The firm's 50 day simple moving average is $5.28 and its 200-day simple moving average is $6.56.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last announced its earnings results on Monday, May 5th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.06). Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The company had revenue of $14.75 million for the quarter, compared to the consensus estimate of $18.12 million. During the same quarter in the previous year, the firm earned ($0.39) earnings per share. The company's revenue for the quarter was up 7.2% compared to the same quarter last year. Equities analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have weighed in on RXRX. Cowen reaffirmed a "hold" rating on shares of Recursion Pharmaceuticals in a report on Friday, February 28th. Needham & Company LLC reduced their price objective on shares of Recursion Pharmaceuticals from $11.00 to $8.00 and set a "buy" rating for the company in a research note on Tuesday, May 6th. Leerink Partners decreased their target price on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating on the stock in a report on Friday, February 28th. Finally, Morgan Stanley cut their price target on shares of Recursion Pharmaceuticals from $10.00 to $8.00 and set an "equal weight" rating for the company in a report on Thursday, April 10th. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $7.60.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.